[{"id":"90ad82b7-7839-4b2c-b09f-4a7055cb4033","acronym":"","url":"https://clinicaltrials.gov/study/NCT05445154","created_at":"2022-07-06T15:54:33.973Z","updated_at":"2024-07-02T16:36:07.690Z","phase":"Phase 1/2","brief_title":"SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT05445154","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • daunorubicin • ruserontinib (SKLB-1028)"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 08/31/2021","start_date":" 08/31/2021","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2022-07-06"},{"id":"df226a48-91d3-42e6-9f95-b3bd2cc6de70","acronym":"ALIVE","url":"https://clinicaltrials.gov/study/NCT04716114","created_at":"2021-03-26T11:56:14.334Z","updated_at":"2024-07-02T16:36:21.704Z","phase":"Phase 3","brief_title":"A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated","source_id_and_acronym":"NCT04716114 - ALIVE","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • fludarabine IV • Synribo (omacetaxine mepesuccinate) • aclarubicin • ruserontinib (SKLB-1028)"],"overall_status":"Recruiting","enrollment":" Enrollment 315","initiation":"Initiation: 03/24/2021","start_date":" 03/24/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2021-11-02"},{"id":"b16bf99b-6ed3-4dd8-bb67-0548496d5441","acronym":"","url":"https://clinicaltrials.gov/study/NCT04015024","created_at":"2021-01-18T19:43:14.861Z","updated_at":"2024-07-02T16:36:58.120Z","phase":"Phase 2a","brief_title":"A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients","source_id_and_acronym":"NCT04015024","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ruserontinib (SKLB-1028)"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2019","start_date":" 07/01/2019","primary_txt":" Primary completion: 04/01/2021","primary_completion_date":" 04/01/2021","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2019-07-16"},{"id":"bb7b2fb1-707b-4ac6-82c5-a95f715e409a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02859948","created_at":"2021-01-18T14:02:21.209Z","updated_at":"2024-07-02T16:37:29.944Z","phase":"Phase 1","brief_title":"A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT02859948","lead_sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ruserontinib (SKLB-1028)"],"overall_status":"Unknown status","enrollment":" Enrollment 18","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 01/01/2018","study_completion_date":" 01/01/2018","last_update_posted":"2016-08-09"}]